Abuse resistant lysine amphetamine compounds

Details Abuse resistant lysine amphetamine compounds Abuse resistant lysine amphetamine compounds

2007-05-29

2007-05-29

Tsang, Cecilia J. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C424S001690

Reexamination Certificate

active

10857619

ABSTRACT:
The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

REFERENCES:
patent: 3028395 (1962-04-01), Gillingham
patent: 3028430 (1962-04-01), Gillingham
patent: 3676492 (1972-07-01), Biel et al.
patent: 3706831 (1972-12-01), Plotnikoff et al.
patent: 3843696 (1974-10-01), Wagner et al.
patent: 3846399 (1974-11-01), Hirschmann et al.
patent: 3878187 (1975-04-01), Schneider et al.
patent: 3884898 (1975-05-01), Schneider
patent: 3975342 (1976-08-01), Gross
patent: 3998799 (1976-12-01), Bodor et al.
patent: 4000280 (1976-12-01), Florvall et al.
patent: 4025501 (1977-05-01), Leute
patent: 4040907 (1977-08-01), Ullman et al.
patent: 4043989 (1977-08-01), Schneider et al.
patent: 4064235 (1977-12-01), Yanaihera et al.
patent: 4064236 (1977-12-01), Dorn et al.
patent: 4297346 (1981-10-01), Rips et al.
patent: 4356166 (1982-10-01), Peterson et al.
patent: 4399121 (1983-08-01), Albarella et al.
patent: 4427660 (1984-01-01), Schiffman et al.
patent: 4457907 (1984-07-01), Porter
patent: 4552864 (1985-11-01), Antoni et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 4801575 (1989-01-01), Pardridge
patent: 4863735 (1989-09-01), Kohn et al.
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 4960790 (1990-10-01), Stella et al.
patent: 4976962 (1990-12-01), Bichon et al.
patent: 5026827 (1991-06-01), Miyazaki
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5183883 (1993-02-01), Tanaka et al.
patent: 5219564 (1993-06-01), Zalipsky et al.
patent: 5233025 (1993-08-01), Miyazaki et al.
patent: 5238714 (1993-08-01), Wallace et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5470997 (1995-11-01), Buechler et al.
patent: 5501987 (1996-03-01), Ordonez et al.
patent: 5529915 (1996-06-01), Phillips et al.
patent: 5534496 (1996-07-01), Lee et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5762909 (1998-06-01), Uzgiris
patent: 5767227 (1998-06-01), Latham et al.
patent: 5846743 (1998-12-01), Janmey et al.
patent: 5851536 (1998-12-01), Yager et al.
patent: 5882645 (1999-03-01), Toth et al.
patent: 5891459 (1999-04-01), Cooke et al.
patent: 5898033 (1999-04-01), Swadesh et al.
patent: 5910569 (1999-06-01), Latham et al.
patent: 5935988 (1999-08-01), Matzke et al.
patent: 5948750 (1999-09-01), Garsky et al.
patent: 5952294 (1999-09-01), Lazo et al.
patent: 5977163 (1999-11-01), Li et al.
patent: 6005004 (1999-12-01), Katz et al.
patent: 6030941 (2000-02-01), Summerton et al.
patent: 6043230 (2000-03-01), Arimilli et al.
patent: 6048736 (2000-04-01), Kosak
patent: 6074659 (2000-06-01), Kunz et al.
patent: 6093391 (2000-07-01), Kabanov et al.
patent: 6235718 (2001-05-01), Balasubramanium
patent: 6255285 (2001-07-01), Kotake
patent: 6258836 (2001-07-01), Shashoua
patent: 6306993 (2001-10-01), Rothbard et al.
patent: 6309633 (2001-10-01), Ekwuribe et al.
patent: 6407137 (2002-06-01), Shashoua
patent: 6458842 (2002-10-01), Dickinson et al.
patent: 6632922 (2003-10-01), Deming et al.
patent: 6680365 (2004-01-01), Deming et al.
patent: 6686446 (2004-02-01), Deming et al.
patent: 6716452 (2004-04-01), Piccariello et al.
patent: 6740641 (2004-05-01), Gao
patent: 6784186 (2004-08-01), Jackson
patent: 6913768 (2005-07-01), Couch et al.
patent: 7105486 (2006-09-01), Mickle et al.
patent: 2001/0031873 (2001-10-01), Greenwald et al.
patent: 2002/0098999 (2002-07-01), Gallop et al.
patent: 2002/0099013 (2002-07-01), Piccariello et al.
patent: 2002/0115725 (2002-08-01), Epstein et al.
patent: 2002/0151526 (2002-10-01), Gallop et al.
patent: 2002/0151529 (2002-10-01), Cundy et al.
patent: 2002/0173468 (2002-11-01), Lerchen et al.
patent: 2002/0183390 (2002-12-01), Javitt
patent: 2003/0077297 (2003-04-01), Chen et al.
patent: 2004/0131680 (2004-07-01), Goldenheim et al.
patent: 2004/0132968 (2004-07-01), Reed et al.
patent: 2004/0204434 (2004-10-01), Shafer
patent: 2005/0038121 (2005-02-01), Mickle et al.
patent: 2005/0054561 (2005-03-01), Mickle et al.
patent: 54168/65 (1965-01-01), None
patent: 0 187 547 (1987-07-01), None
patent: 0634999 (1993-10-01), None
patent: 1421130 (1965-01-01), None
patent: 1092089 (1967-11-01), None
patent: 1112347 (1968-05-01), None
patent: 55007242 (1980-01-01), None
patent: 55028915 (1980-02-01), None
patent: 4112858 (1992-04-01), None
patent: 7165684 (1995-06-01), None
patent: 6414901 (1964-12-01), None
patent: WO 93/20048 (1993-10-01), None
patent: WO 95/12605 (1995-05-01), None
patent: WO 95/14033 (1995-05-01), None
patent: WO 97/36616 (1997-10-01), None
patent: WO 98/04277 (1998-02-01), None
patent: WO 98/48824 (1998-11-01), None
patent: WO 02/34237 (2002-05-01), None
patent: WO 03/03498 (2003-05-01), None
Aggarwal, et al., “Synthesis and Biological Evaluation of Prodrugs of Zidovudine,”J. Med. Chem., 33(5):1505-1511 (1990).
Amidon, G., et al., “A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation ofin VitroDrug Product Dissolution andin VivoBioavailability,”Pharmaceutical Research, vol. 12, No. 3 (1995).
Amidon, G.L., et al., “5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT are Absorbed by the Intestinal PEPT1 Peptide Transporter,”Pharm Res, 16(2):175 (1999), Abstract.
Balimane, P., et al., “Effect of Ionization on the Variable Uptake of Valacyclovir via the Human Intestinal Peptide Transporter (hPepT1) in CHP cells,”Biopharm Drug Dispos, 21(5):165-174 (2000), Abstract.
Balimane, P.V., et al., “Direct Evidence for Peptide Transporter (PepT1)-Mediated Uptake of a Nonpeptide Prodrug, Valacyclovir,”Biochem Biophys Res Commun, 250(2):246-251 (1998), Abstract.
Bunevicius, R., “Effects of Thyroxine as Compared with Thyroxine Plus Triiodothyronine in Patients with Hypothyroidism,”The New England Journal of Medicine, vol. 340, No. 6 (1999).
Burnettem, Thimysta C., et al., “Metabolic Disposition of the Acyclovir Prodrug Valaciclovir in the Rat,”Drug Metabolism and Disposition, 22(1):60-64 (1994).
Canaris, G., “The Colorado Thyroid Disease Prevalence Study,” Archives Internal Medicine Articles and Abstracts, vol. 160, No. 4 (2000).
De Vrueh, Remco L.A., et al, “Transport of L-Valine-Acyclovir Via the Oligopeptide Transporter in the Human Intestinal Cell Line, Caco-2,”Journal of Pharmacology and Experimental Therapeutics, 286(2):1166-1170 (1988).
Friedrichsen, G.M., et al., “Model Prodrugs Designed for the Intestinal Peptide Transporter. A Synthetic Approach for Coupling of Hydroxy-Containing Compounds to Dipeptides,”Eur J Pharm Sci, 14(1):13-19 (2001, Abstract.
Guo, A., et al., “Interactions of a Nonpeptidic Drug, Valacyclovir, with the Human Intestinal Peptide Transporter (hPEPT1) Expressed in a Mammalian Cell Line,”Pharmacol Exp Ther, 289(1):448-454 (1999), Abstract.
Han H., et al., “5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT and Absorbed by the Intestinal PEPT1 Peotide Transporter,”Pharm Res, 15(8):1154-1159 (1998), Abstract.
Han, H.K., et al., “Cellular Uptake Mechanism of Amino Acid Ester prodrugs in Caco-2hPEPT1 Cells Overexpressing a Human Peptide Transporter,”Pharm Res, 15(9):1382-1386 (1998), Abstract.
Han,

Affiliated with

Also associated with

Rating

Abuse resistant lysine amphetamine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Abuse resistant lysine amphetamine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Abuse resistant lysine amphetamine compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3743015